BACKGROUND
Latest global cancer data
One in 5 people develop cancer during their lifetime
One in 8 men die from cancer
One in 11 women die from cancer
The global cancer burden is estimated to have risen to 19.3 million new cases and 10.0 million deaths in 2020.1 One in 5 people worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.
Latest global cancer data
Major cancer types in 2020
The 10 most common cancer types account for more than 60% of the newly diagnosed cancer cases and more than 70% of the cancer deaths. Female breast cancer is the most commonly occurring cancer worldwide (11.7% of the total new cases), followed by lung cancer (11.4%), colorectal cancer (10.0%), prostate cancer (7.3%), and stomach cancer (5.6%).
In men, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by prostate cancer and colorectal cancer for incidence and liver cancer and colorectal cancer for mortality.
In women, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal cancer and lung cancer for incidence and lung cancer and colorectal cancer for mortality.
1
Female Breast Cancer 11.7%
2
Lung Cancer 11.4%
3
Colorectal Cancer 10.0%
4
Prostate Cancer 7.3%
5
Stomach Cancer 5.6%
Important Health Screening
Early detection can clearly have a huge benefit. A person whose cancer is found before it has spread to other parts of the body is more than four times as likely to survive five years than a person diagnosed with advanced disease. In patients with lung cancer, the difference is more than tenfold. Recent models suggest that shifting the stage of diagnosis from metastatic to localized cancers could potentially reduce five-year cancer-related mortality by up to 24 percent in people aged 50–79 years old.
Early cancer diagnosis
saves lives,
cuts treatment costs
Early cancer diagnosis
Cuts treatment costs
Strategies to improve early diagnosis can be readily built into health systems at a low cost. In turn, effective early diagnosis can help detect cancer in patients at an earlier stage, enabling treatment that is generally more effective, less complex, and less expensive. For example, studies in high-income countries have shown that treatment for cancer patients who have been diagnosed early are 2 to 4 times less expensive compared to treating people diagnosed with cancer at more advanced stages.
OUR SOLUTION
Breast Cancer CA 15-3 Rapid Test Kits
By quickly diagnosing tumor makers(CA: Cancer Antigen), we can easily self-test for the diagnosis of cancers by ourselves, so we can easily test whether or not cancer occurs.
Features and Benefits:
1
Provides simple positive or negative results for CA15-3 levels in blood.
2
Read results in 15 minutes.
3
These tests are designed to be used by home test as well as medical professionals.
OUR TECHNOLOGY
Breast Cancer & CA(Cancer Antigen) 15-3
CA15-3 is one of the Food and Drug Administration (FDA)-approved tumor makers for monitoring breast cancer.
CA15-3 is a protein that is also produced in normal breast cells. In many breast cancer patients, the production of CA15-3 and CA 27.29 is increased. CA15-3 does not cause cancer, but is secreted from tumor cells and enters the bloodstream, thereby becoming useful as a tumor maker to track the course of cancer. CA15-3 is elevated in about 10% of women with early-stage localized breast cancer and about 70% of women with metastatic breast cancer. CA15-3 may be elevated in healthy individuals and may also be elevated in other cancers or other conditions such as colorectal cancer, lung cancer, cirrhosis, hepatitis and benign breast disease.
 |  |  |  |
|---|---|---|---|
 |